Effect of carvedilol on pulse pressure and left ventricular hypertrophy in spontaneously hypertensive rats with adriamycin nephropathy

Biomedicine and Pharmacotherapy

Volumn 63, Issue 8, 2009, Pages 571-576

  Jovanovic, Dijana ^a   Jovovic, Djurdjica ^b   Mihailovic Stanojevic, Nevena ^b   Miloradovic, Zoran ^b   Naumovic, Radomir ^a   Dimitrijevic, Jovan ^a   Maksic, Nebojsa ^a   Djukanovic, Ljubica ^a  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Adriamycin nephropathy; Left ventricular hypertrophy; Pulse pressure; Rats

Indexed keywords

CAPTOPRIL; CARVEDILOL; CREATININE; DOXORUBICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHRONIC KIDNEY FAILURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE CLEARANCE; DIASTOLIC BLOOD PRESSURE; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; MEAN ARTERIAL PRESSURE; MONOTHERAPY; NONHUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEINURIA; PULSE PRESSURE; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CAPTOPRIL; CARBAZOLES; CREATININE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOXORUBICIN; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; PROPANOLAMINES; PROTEINURIA; RATS; RATS, INBRED SHR; TIME FACTORS;

EID: 70349420142     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2008.10.006     Document Type: Article

References (33)

1. Kannel W.B., Dawber T.R., and McGee D.L. Perspectives on systolic hypertension. The Framingham study. Circulation 61 (1980) 1179-1182
2. Birkenhager W.H., and De Leeuw P.W. The older hypertensive. Blood Press 10 (2001) 299-310
3. Franklin S.S., Khan S.A., Wong N.D., Larson M.G., and Levy D. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham heart study. Circulation 100 (1999) 354-360
4. Stolarz K, Staessen JA. Prognostic significance of pulse pressure. 9th European meeting on cardionephrology, Italy. Editoriale Bios; 2002. p. 257-60.
5. Franklin S.S. Cardiovascular risks related to increased diastolic, systolic and pulse pressure. An epidemiologist's point of view. Pathol Biol 47 (1999) 594-603
6. Domanski M., Mitchell G., Pfeffer M., Neaton J.D., Norman J., Svendsen R., et al. Pulse pressure and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT). J Am Med Assoc 287 (2002) 2677-2683
7. Tozawa M., Iseki K., Iseki C., and Takishita S. Pulse pressure and risk of total mortality and cardiovascular events in patients on chronic hemodialysis. Kidney Int 61 (2002) 717-726
8. Benetos A., Safar M., Rudnichi A., Smulyan H., Richard J.L., Ducimetriere P., et al. Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension 30 (1997) 1410-1415
9. Mannucci E., Lambertucci L., Monami M., Fedeli A., Chiasserini V., Marchionni N., et al. Pulse pressure and mortality in hypertensive type 2 diabetic patients. A cohort study. Diabetes Metab Res Rev 22 (2006) 172-175
10. Jovanovic D., Dimitrijevic J., Varagic J., Jovovic D., Starcevic A., and Djukanovic L. Effects of captopril on morphologic changes in kidney of spontaneously hypertensive rats with adriamycin nephropathy. Ren Fail 20 (1998) 451-458
11. Bader H., and Mayer D.S. The size of the juxtaglomerular apparatus in diabetic glomerulosclerosis and its correlation with arteriosclerosis and arterial hypertension: a morphometric light microscopic study on human renal biopsies. Clin Nephrol 8 (1977) 308-311
12. Mann J.F.E., Reisch C., and Ritz E. Use of angiotensin-converting enzyme inhibitors for the preservation of kidney function. Nephron 55 Suppl. 1 (1990) 38-42
13. Jafar T.H., Stark P.C., Schmid C.H., Landa M., Maschio G., de Jong P.E., et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 139 (2003) 244-252
14. Siebenhofer A., Plank J., Horvath K., Berghold A., Sutton A.J., Sommer R., et al. Angiotensin receptor blockers as anti-hypertensive treatment for patients with diabetes mellitus: meta-analysis of controlled double-blind randomized trials. Diabet Med 21 (2004) 18-25
15. Kanazawa M., Kohzuki M., Yoshida K., Kurosawa H., Minami N., Saito T., et al. Combination therapy with an angiotensin-converting enzyme (ACE) inhibitor and a calcium antagonist: beyond the renoprotective effects of ACE inhibitor monotherapy in a spontaneous hypertensive rat with renal ablation. Hypertens Res 25 (2002) 447-453
16. Jovanovic D., Jovovic D., Varagic J., Dimitrijevic J., Djukanovic L., and Dragojlovic Z. Slowing down of chronic renal failure progression with captopril in spontaneously hypertensive rats with adriamycin nephropathy. Srp Arh Celok Lek 130 3-4 (2002) 73-80
17. Jovanović D., Jovović D., Mihailović-Stanojević N., Miloradović Z., Dimitrijević Z., Maksić N., et al. Influence of carvedilol on chronic renal failure progression in spontaneously hypertensive rats with adriamycin nephropathy. Clin Nephrol 63 (2005) 446-453
18. Stojceva-Taneva O., Selim G., Stojkovski L., and Ivanovski N. Hypertension and progression of nephropathy in diabetic and non-diabetic chronic kidney disease patients. Hippokratia 11 (2007) 72-76
19. Sabino B., Lessa M.A., Nascimento A.R., Rodrigues C.A., Henriques M.G., Garzoni L.R., et al. Effects of antihypertensive drugs on capillary rarefaction in spontaneously hypertensive rats: intravital microscopy and histologic analysis. J Cardiovasc Pharmacol 51 (2008) 402-409
20. Xie H.H., Shen F.M., Xu L.P., Han P., Miao C.Y., and Su D.F. Reduction of blood pressure variability by combination therapy in spontaneously hypertensive rats. J Hypertens 25 (2007) 2334-2344
21. Foley R.N., Parfrey P.S., Harnett J.D., Kent G.M., Murray D.C., and Barre P.E. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 49 (1996) 1379-1385
22. Iseki K., and Fukiyama K. Predictors of stroke in patients receiving chronic hemodialysis. Kidney Int 50 (1996) 1672-1675
23. Mitchell G.F., Moye L.A., Braunwald E., Rouleau J.L., Bernstein V., Geltman E.M., et al. Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. Circulation 96 (1997) 4254-4260
24. Bonner G. Risk evaluation and therapeutical implications of pulse pressure in primary arterial hypertension. Dtsch Med Wochenschr 127 (2002) 2396-2399
25. Bellenger N.G., Rajappan K., Rahman S.L., Lahiri A., Raval U., Webster J., et al. Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: a cardiovascular magnetic resonance study. Heart 90 (2004) 760-764
26. Paraskevaidis I., Farmakis D., Parissis J.T., Dodouras T., Filippatos G., Tsiapras D., et al. Carvedilol improves left atrial and left ventricular function and reserve in dilated cardiomyopathy after 1 year of treatment. J Card Fail 13 (2007) 108-113
27. Firshman W.H. Carvedilol. N Engl J Med 339 (1998) 1759-1765
28. Brooks D.P., Short B.G., Cyronak M.J., Contino L.C., DiCristo M., Wang Y.X., et al. Comparison between carvedilol and captopril in rats with partial ablation-induced chronic renal failure. Br J Pharmacol 109 (1993) 581-586
29. Wong V.Y., Laping N.J., Nelson A.H., Contino L.C., Olson B.A., Gygielko E., et al. Renoprotective effects of carvedilol in hypertensive-stroke prone rats may involve inhibition of TGF beta expression. Br J Pharmacol 134 (2001) 977-984
30. Van den Branden C., Gabriels M., Vamecq J., Vanden Houte K., and Verbeelen D. Carvedilol protects against glomerulosclerosis in rat remnant kidney without general changes in antioxidant enzyme status. A comparative study of two beta-blocking drugs, carvedilol and propranolol. Nephron 77 (1997) 319-324
31. Rodriguez Perez J.C., Losada A., Anabitarte A., Cabrera J., Llobert J., Palop L., et al. Effects of the novel multiple action agent carvedilol on severe nephrosclerosis in renal ablated rats. J Pharmacol Exp Ther 283 (1997) 336-344
32. Kett M.M., Denton K.M., Boesen E.I., and Anderson W.P. Effects of early carvedilol treatment and withdrawal on the development of hypertension and renal vascular narrowing. Am J Hypertens 17 (2004) 161-166
33. Ohlstein E.H., Douglas S.A., Po Sung C., Yue T., Louden C., Arleth A., et al. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc Natl Acad Sci U S A 90 (1993) 6189-6193